An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A.

Expert Review of Hematology
Ana Boban, Cedric Hermans

Abstract

Introduction: Hemophilia A is an inherited disorder that is characterized by decreased or absent factor (F)VIII and an increased risk of bleeding. Clinical presentation of the severe form of the disease includes spontaneous bleeding into the joints and muscles, while patients with milder forms usually exhibit trauma-associated bleeding. The treatment of hemophilia aims to prevent bleeding. A number of clotting FVIII concentrates are available for managing hemophilia A, which have different safety and efficacy characteristics. Advancements in biotechnology have enabled development of recombinant factor concentrates, which thus minimize the risk of transmitting infectious diseases. Turoctocog alfa (NovoEight®, Novo Nordisk A/S, Bagsvaerd, Denmark) was the first third-generation B-domain truncated recombinant FVIII.Areas covered: The manuscript describes the characteristics of turoctocog alfa, as well as its efficacy and safety for prophylaxis and on-demand treatment for patients with severe hemophilia A without inhibitors.Expert opinion: In clinical trials, turoctocog alfa has demonstrated very good efficacy and safety for the prophylaxis and on-demand treatment of hemophilia A patients, as well as high hemostatic activity during...Continue Reading

References

Dec 1, 1990·Journal of Internal Medicine·F R RosendaalE Briët
Aug 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·J J TooleR J Kaufman
Jan 5, 1999·Haemophilia : the Official Journal of the World Federation of Hemophilia·T W BarrowcliffeA R Hubbard
Jul 13, 2001·Seminars in Hematology·M MikaelssonM A Jankowski
Mar 12, 2002·Haemophilia : the Official Journal of the World Federation of Hemophilia·S RoyalUNKNOWN European haemophilia economics study group
Feb 1, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·J M LusherUNKNOWN ReFacto Phase 3 Study Group
Mar 18, 2003·Seminars in Thrombosis and Hemostasis·Goris Roosendaal, Floris P J G Lafeber
Apr 24, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·E BerntorpC Hart
Apr 24, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·K FischerH M van den Berg
May 7, 2005·Haemophilia : the Official Journal of the World Federation of Hemophilia·J M Lusher, D A Roth
Jan 18, 2006·Methods in Enzymology·Katalin F Medzihradszky
Feb 3, 2007·Journal of Thrombosis and Haemostasis : JTH·J AstermarkUNKNOWN MIBS Study Group
Aug 10, 2007·The New England Journal of Medicine·Marilyn J Manco-JohnsonBruce L Evatt
Mar 28, 2008·Acta Haematologica·Kate KhairBeverly A Christie
May 28, 2008·Journal of Thrombosis and Haemostasis : JTH·V S BlanchetteUNKNOWN rAHF-PFM Clinical Study Group
Nov 13, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·L ThimT D Steenstrup
Jun 16, 2010·Haemophilia : the Official Journal of the World Federation of Hemophilia·M L S ChristiansenM Kjalke
Jan 25, 2011·Journal of Thrombosis and Haemostasis : JTH·A GringeriUNKNOWN ESPRIT Study Group
Mar 24, 2011·Haemophilia : the Official Journal of the World Federation of Hemophilia·D ViuffD Lillicrap
Jul 21, 2011·Haemophilia : the Official Journal of the World Federation of Hemophilia·T ElmM Tranholm
Dec 22, 2011·Seminars in Thrombosis and Hemostasis·Roshni Kulkarni, J Michael Soucie
Jan 4, 2012·Journal of Thrombosis and Haemostasis : JTH·L A ValentinoUNKNOWN Prophylaxis Study Group
Feb 9, 2012·Seminars in Thrombosis and Hemostasis·Antonio CoppolaMassimo Franchini
Jun 12, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·P F NielsenB Vandahl
Dec 12, 2012·Blood·Jan AstermarkUNKNOWN Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
Jan 18, 2013·The New England Journal of Medicine·Samantha C GouwUNKNOWN PedNet and RODIN Study Group
Jul 3, 2013·Blood Reviews·Massimo Franchini, Pier Mannuccio Mannucci
Jan 30, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·E SantagostinoA Iorio
Apr 29, 2014·European Journal of Haematology·Massimo Morfini
May 7, 2014·European Journal of Haematology·Mirella EzbanMarianne Kjalke
Jul 24, 2014·Pharmacotherapy·Niyati H VakilSylvia Martin-Stone
Aug 30, 2014·Journal of Internal Medicine·M Osooli, E Berntorp
Oct 3, 2014·Haemophilia : the Official Journal of the World Federation of Hemophilia·E SantagostinoI Matytsina
Dec 31, 2014·Drug Design, Development and Therapy·Elena Santagostino
Feb 14, 2015·Haemophilia : the Official Journal of the World Federation of Hemophilia·M OzeloA K Busk
Apr 8, 2015·Drug Design, Development and Therapy·Hideyuki Takedani, Jun Hirose

❮ Previous
Next ❯

Citations

Aug 8, 2021·Stem Cell Research & Therapy·Amal Elham FaresRokia Mohamad Hassan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.